Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

Blood (2025) 146 (Supplement 1): 3862.

https://doi.org/10.1182/blood-2025-3862

Published: 2025

Journal Articles

LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring

Blood (2025) 146 (Supplement 1): 3293.

https://doi.org/10.1182/blood-2025-3293

Published: 2025

Journal Articles

Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey

Dimpy Modi, Brett Houston, Brian Leber, Erin Jamula, Nancy Heddle, Tobias Berg, Donald Arnold

Blood (2025) 146 (Supplement 1): 1364.

https://doi.org/10.1182/blood-2025-1364

Published: 2025

Journal Articles

High response rates and early treatment patterns with venetoclax and azacitidine from the prospective liven study: Real-world AML care in Canada

Kristjan Paulson, Lalit Saini, Michelle Geddes, Alejandro Garcia-Horton, Stephanie Corriveau-Désilets, Nicole Laferriere, Adi Klil-Drori, Fella Tamzalit, Guylaine Roy, Brian Leber

Blood (2025) 146 (Supplement 1): 6411.

https://doi.org/10.1182/blood-2025-6411

Published: 2025

Journal Articles

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Blood (2025) 146 (Supplement 1): 964.

https://doi.org/10.1182/blood-2025-964

Published: 2025

Journal Articles

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Blood (2024) 144 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2024-211183

Published: 2024

Journal Articles

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Blood (2024) 144 (Supplement 1): 4583.

https://doi.org/10.1182/blood-2024-194441

Published: 2024

Journal Articles

The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Emily E Hartung, Kanwaldeep Singh, Sarah Coopersmith, Jamie Avrumutsoae, Siddaarth Varatharajan, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Ronan Foley, Brian Leber, Irwin Walker, Kylie L. Lepic, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2024) 144 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2024-199648

Published: 2024

Journal Articles

Canadian Real-World Data for Acute Myeloid Leukemia Chemotherapy-Ineligible Patients on Venetoclax: An Interim Analysis from the Prospective Liven Study

Kristjan Paulson, Thomas Dunne, Lalit Saini, Nicole B. Laferriere, Michelle Geddes, Stephanie Desilets, David Sanford, Leanne Genge, Paola Lembo, Pierre-Andre Fournier, Brian Leber

Blood (2024) 144 (Supplement 1): 6069.

https://doi.org/10.1182/blood-2024-203473

Published: 2024

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant

Michael Radford, Alejandro Garcia-Horton, Rohail Badami, Elaine Jin, Nida Javed Usmani, Daria Grafodatskaya, Elizabeth McCready, Dina Khalaf, Irwin Walker, Brian Leber, Kylie L. Lepic, Gregory Pond, Tobias Berg

Blood (2023) 142 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2023-187458

Published: 2023

Journal Articles

Ureaplasma -Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant

Rohail Badami, Kylie L. Lepic, Dina Khalaf, Alejandro Garcia-Horton, Tobias Berg, Brian Leber, Irwin Walker, Michael Radford

Blood (2023) 142 (Supplement 1): 6988.

https://doi.org/10.1182/blood-2023-182897

Published: 2023

Journal Articles

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Kanwaldeep Singh, Emily Hartung, Christina Muhs, Islam Alshamleh, Monisha Divakaran, Anna Dvorkin-Gheva, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Stephen Ronan Foley, Brian Leber, Irwin Walker, Kylie Lepic, Harald Schwalbe, Hubert Serve, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2023) 142 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2023-189515

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Yu Yan, Kanwaldeep Singh, Emily Hartung, Brendan Lee, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Brian Leber, Irwin Walker, Kylie L. Lepic, Maria Kleppe, Hugh Young Young Rienhoff Jr., Jr., Jonathan Bramson, Tobias Berg

Blood (2023) 142 (Supplement 1): 6793.

https://doi.org/10.1182/blood-2023-188472

Published: 2023

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

Journal Articles

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1601–1603.

https://doi.org/10.1182/blood-2022-170147

Published: 2022

Journal Articles

A Retrospective Cohort Study of Donor Cell Leukemia

Brittany Salter, Omar Raslan, Suzanne Demczuk, Brian Leber, Alejandro Garcia-Horton, Irwin Walker, Tobias Berg, Darci Butcher, Kylie L. Lepic, Elizabeth McCready, Parveen Wasi, Dina Khalaf

Blood (2022) 140 (Supplement 1): 12916–12917.

https://doi.org/10.1182/blood-2022-164643

Published: 2022

Journal Articles

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Blood (2022) 140 (Supplement 1): 9122–9124.

https://doi.org/10.1182/blood-2022-171107

Published: 2022

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring

Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey

High response rates and early treatment patterns with venetoclax and azacitidine from the prospective liven study: Real-world AML care in Canada

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Canadian Real-World Data for Acute Myeloid Leukemia Chemotherapy-Ineligible Patients on Venetoclax: An Interim Analysis from the Prospective Liven Study

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant

Ureaplasma -Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

A Retrospective Cohort Study of Donor Cell Leukemia

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only